Swiss giant Roche Pharma said on Wednesday that it is working with Indian authorities to accelerate the emergency-use authorisation (EUA) for its investigational antibody cocktail (Casirivimab and Imdevimab) in India.
It is seeking an EUA in India based on the data filed for getting the EUA in the US and also scientific opinion of the Committee for Medicinal Products for Human Use (CHMP) in the EU. Once it gets an EUA here, it can import the globally manufactured product batches to India as soon as possible, the company said.
It added that it is also trying to expand production of tocilizumab (brand